Centogene N.V. (CNTG)
After hours:
| Previous close | 1.3200 |
| Open | 1.3500 |
| Bid | 1.3000 x 1000 |
| Ask | 1.3500 x 2900 |
| Day's range | 1.2903 - 1.3500 |
| 52-week range | 0.6800 - 4.9400 |
| Volume | |
| Avg. volume | 29,125 |
| Market cap | 35.341M |
| Beta (5Y monthly) | -1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1970 |
| Earnings date | 28 Mar 2023 - 03 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.51 |
- Business Wire
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & ROSTOCK, Germany & BERLIN, January 10, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rar
- GlobeNewswire
CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization for Parkinson’s disease (PD)The Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of disease progression, diagnosis, and treatment for patientsHaving recently reached a significant milestone of testing over 12,500 participants, the study now aims to recruit and genetic
- PR Newswire
Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development
Premier Research, whose mission is to help the most innovative biotech and medtech companies take their best ideas from concept to commercialization, and Centogene N.V. [Nasdaq: CNTG], the essential life science partner for data-driven answers in rare and neurodegenerative diseases, have announced a strategic partnership to provide end-to-end support in rare disease clinical trials. The collaboration aims to improve patient identification, stratification, recruitment, and enrollment, thereby inc
